Crispr Therapeutics shares tumble after significant earnings miss
Alphatec Holdings , Inc. (NASDAQ:ATEC), a medical device company with a market capitalization of $1.57 billion, saw its Executive Vice President of Sales, David Sponsel, recently execute a significant stock sale. According to the latest SEC filing, Sponsel sold a total of 32,365 shares of common stock over two days, February 24 and February 25. The transactions were conducted under a Rule 10b5-1 trading plan, designed to meet tax withholding obligations linked to the vesting of restricted stock units. According to InvestingPro data, ATEC’s stock has surged 75% over the past six months.
The shares were sold at a weighted average price, with the February 24 transaction involving 12,946 shares at prices ranging from $10.47 to $10.93. The following day, 19,419 shares were sold at prices ranging from $10.13 to $10.64. The total value of these sales amounted to approximately $341,062. The stock currently trades at $11.06, and InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value.
Post-transaction, Sponsel continues to hold 702,709 shares of Alphatec Holdings, maintaining a substantial stake in the company. Despite recent insider selling, ATEC maintains strong fundamentals with a healthy current ratio of 2.32 and impressive revenue growth of 27.2% in the last twelve months. For deeper insights into ATEC’s valuation and performance metrics, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Alphatec Holdings Inc. reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of -$0.23, which missed analysts’ expectations of -$0.05. However, the company saw a positive revenue surprise, achieving $177 million in revenue compared to the forecasted $170.35 million. This represented a 28% year-over-year increase, driven by strong performances in surgical and EOS revenue streams. Despite the revenue beat, the EPS miss was significant, leading to a decline in investor sentiment. Looking ahead, Alphatec has set a revenue guidance of $732 million for 2025, indicating a projected 20% growth. The company also anticipates positive cash flow and an adjusted EBITDA of $75 million for the upcoming year. Notably, Alphatec’s strategic focus on product launches, including navigation robotics, is expected to further support growth. In terms of analyst activity, the earnings report did not mention any specific upgrades or downgrades from financial firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.